

Certificate of analysis

SFC866-03-02

Operator: Jane Vowles Date: 17/03/2015

Supervisor: Sally Cowley Date: 01.03.2016


Signature: SA Consley

Source of fibroblasts and reprogramming information

- SF866 from UOXF
- 28/05/2014
- Reprogrammed at UOXF JMSCF
- Reprogrammed on 02/10/2014 at passage 4
- Cytotune v2 WP3 SOP10


Viability post-thaw and Morphology according to SOP19 passage 16

- Cell count immediately post-thaw 4.8 x 10⁶
- Viability immediately post-thaw 82.9%
- Photo at 24h post-thaw (scale bar = $100\mu m$):



Sendai clearance: according to WP3 SOP15 undetectable at passage 16





SFC866-03-02

SFC866-03-06 SFC870-03-06

SFC870-03-08

+ control

Product sizes: SeV 181bp; KOS 528bp; SeV-Klf 410bp; SeV-Myc 532bp; Actin 92bp

Mycoplasma Test: According to MycoAlert Lonza LT07-318 undetectable at passage 16

Sample	Clone	Passage number	Initial	Reading 1	Reading 2	Ratio/Status
+ve control				5.084	148.1	29.13
-ve control				4.485	0.531	0.12
6	SFC866-03-02	p9+7	JV	3.127	1.46	0.47

Results mean


Ratio 0 - 0.999 negative for mycoplasma

Ratio 1 – 1.3 Borderline Result (retest required)


Ratio above 1.3 positive for mycoplasma

Flow cytometric analysis according to WP3 SOP 20 and 21 passage p17

Tra-1-60:



NANOG:



SNP analysis according to WP3 SOP Preparation of DNA and RNA samples for Illumina arrays

- Passage no. 16
- Identity to parent fibroblasts confirmed
- Karyotype abnormalities: none detected
- For details and raw data see StemDB